*Disseminated on Behalf of Quantum BioPharma Ltd. Market Crux Announces Coverage On (QNTM) Starting This Morning
—Thursday, August 7, 2025
(QNTM) Comes Backed By Several Potential Catalysts Like…
Analyst Target: Singular Research Raised Its 12-Month Target For (QNTM) To $35.50, Indicating (Approx.) 42% Upside Potential From Its Recent Range.
Recent Momentum: (QNTM) Just Moved (Approx.) 71% In The Past Month, And Over (Approx.) 1,300% In Six Months After Our Last Highlight. Razor-Thin Float: With Fewer Than 2.6M Shares Available, (QNTM) Has The Potential For Big Moves—Even With Small Shifts In Demand
Technical Strength: (QNTM) Is Trending Above All Major Moving Averages Tracked By Barchart Across Short-, Mid-, And Long-Term Timeframes.
Pull Up (QNTM) This Morning While It's Still Early… August 7, 2025 Thursday Morning Watchlist | See Why (QNTM) Just Hit Our Radar Today Dear Reader, If you haven't pulled up (QNTM) yet, now's the time. Technical indicators are stacking up fast—TradingView's dashboard is flashing multiple bullish signals, and Barchart confirms it's trending above all major moving averages. The last time we brought Quantum BioPharma (NASDAQ: QNTM) to your radar, it went on to post a move of approximately 400% in around 3 months.. This morning, a brand-new filing just dropped—and it may be the most revealing update yet. From the end of Q1 to the close of Q2, (QNTM) moved approximately 160%—from $7.71 to $20.25—and now the company's latest quarterly report confirms why momentum may still be building. (QNTM) just reported one of the strongest quarters we've seen from a clinical-stage company this year: - Rising total assets quarter-over-quarter
- Over $500K in cry-pto gains
- Zero debt remaining after debenture conversion
- Advancing MS trials and PET imaging with Mass General
- unbuzzd™ pre-IPO in motion—no dilution to QNTM shareholders
This is no small update—and if recent history is any indication, it may be worth watching what happens next. Read this morning's news release here. Quantum BioPharma (NASDAQ: QNTM) is back on our watchlist today—this time off the back of a major clinical development. The company just released positive results from its Phase 1 Multiple Ascending Dose (MAD) trial for Lucid-MS—a first-in-class therapeutic candidate aimed at targeting the root mechanism of multiple sclerosis (MS), not just the symptoms. According to the official Clinical Study Report (CSR), Lucid-MS was found to be both safe and well-tolerated in healthy participants—a key hurdle cleared and a green light for the company to advance toward an Investigational New Dr-ug (IND) filing with the FDA, anticipated in Q4 2025. With multiple programs now advancing in parallel, and this milestone behind them, (QNTM) could be entering one of the most eventful phases in its timeline so far. Analyst Raises Target On Quantum BioPharma
Singular Research recently reaffirmed its bullish rating on (QNTM), lifting its 12-month target to $35.50 from $12.90. The revised target reflects growing momentum across multiple fronts, including: - A pending IND submission for Lucid-MS
- FSD202 preparing for a Phase 2 trial
- Advancing steps toward the Unbuzzd™ Wellness IPO
- Potential contingent value rights tied to litigation proceeds exceeding $700M
This updated outlook suggests an approximate 42% potential upside from (QNTM)'s recent range, driven by what analysts see as multiple near-term value drivers. According to Yahoo, (QNTM)'s public float sits below 2.6M shares — a situation where even a small shift in demand could spark the potential for big moves. In fact, the last time we brought you (QNTM) was on the morning of Thursday, March 27, 2025; when it opened around $7.36, and over the following 3 months it made it to $38.25 on June 20 — marking an approximate move of more than 419%. 
Over the past month, (QNTM) has already shown what a shift in momentum can look like — moving approximately 71% from $16.39 on July 9 to $28.15 on August 4. That kind of move in a short window, paired with the latest developments, has only amplified interest. According to Barchart numbers, (QNTM) is currently trending above every major moving average it tracks, spanning short-, mid-, and long-term timeframes. This kind of alignment could be signaling the potential for continued momentum — and it's a key reason why (QNTM) is topping our watchlist right now. Not Your Typical BioPharma—(QNTM)'s Lucid-MS May Be
Entering a League of Its Own
(QNTM) isn't your typical clinical-stage biopharmaceutical name. Through its wholly owned subsidiary Lucid Ps-ych-eceut-icals Inc., the company is developing Lucid-MS, a patented New Chemical Entity with a unique non-immunomodulatory approach. Preclinical data shows the compound's ability to prevent and even reverse myelin degradation — a hallmark of MS and other neurodegenerative diseases. Unlike conventional MS therapies that primarily modulate the immune system, Lucid-MS is aimed at neuroprotection — a therapeutic angle many experts believe will be the next frontier in treating demyelinating diseases. And now, with both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) trials complete, the company is advancing toward Phase 2 efficacy trials in MS patients — a move that could put it on the radar of major healthcare players. (QNTM) Builds a Multi-Domain Pipeline with Science, Speed, and Structure
While Lucid-MS is the scientific flagship, (QNTM)'s story extends well beyond multiple sclerosis. FSD202 – Recently cleared for a Phase 2 trial in nociplastic pain associated with Idiopathic Mast Cell Activation Syndrome (MCAS). There's currently no cure for MCAS, and FSD202 could address a substantial unmet need. - Unbuzzd™ – A science-backed, rapid alcohol detoxification beverage designed to accelerate alcohol metabolism, restore mental alertness, and support faster recovery. According to Grand View Research, the global hangover cure products market was valued at $2.05B in 2022 and is projected to grow to $6.2B by 2030 at a 14.8% CAGR. As the first-to-market product in this category backed by clinical results, Unbuzzd™ is positioned to capture a share of that growth.
- (QNTM) earns 7% royalties up to $250M in cumulative payments (then 3% in perpetuity) and retains 100% of pharmaceutical and medical rights to develop similar formulations for clinical use.
- Strategic In-vest-ments – Managed through FSD Strategic In-vest-ments Inc., holding secured loans backed by residential and commercial property.
This combination of therapeutic innovation, consumer health products, and asset-backed in-vest-ments provides multiple potential value streams — rare for a company of this size and stage. What's Unfolding Right Now Is Tough to Overlook
The latest Clinical Study Report isn't just another milestone—it could mark a definitive turning point. With early-stage safety concerns now off the table, Lucid-MS moves one step closer to patient trials and a formal IND submission with the FDA. But it's not just the clinical progress that stands out. (QNTM) is also advancing a multi-asset pipeline, lining up near-term potential catalysts across multiple programs, attracting ongoing analyst coverage with raised targets, and operating with a public float that remains tightly held. When you step back and consider the full picture, the setup here is difficult to ignore—and that's exactly why (QNTM) just hit our radar. 7 Reasons Why (QNTM) Is At The Top Of Our Screens This Morning
—Thursday, August 7, 2025
1. Upgraded Analyst Target: Singular Research lifted its 12-month target for (QNTM) to $35.50 from $12.90, citing multiple near-term catalysts. Singular's target suggests around 42% upside potential from its recent range.
2. Recent Momentum: over the past month, (QNTM) has moved approximately 71% from $16.39 on July 9 to $28.15 on August 4, highlighting the potential for short-term momentum. Last time we highlighted this profile it made an approximate move of more than 419% in 3 months.
3. Razor-Thin Float: with fewer than 2.6M shares in the public float, (QNTM) has the kind of structure where even a small shift in demand could lead to the potential for big moves. 4. Technical Strength: (QNTM) is currently trading above all major moving averages tracked by Barchart, spanning short-, mid-, and long-term timeframes. 5. Major Clinical Milestone: (QNTM) just reported positive results from its Phase 1 Multiple Ascending Dose trial for Lucid-MS, confirming safety and tolerability in healthy participants. 6. Diverse Revenue Paths: with clinical-stage programs, consumer health royalties, and secured property-backed in-vest-ments, (QNTM) has multiple avenues for potential value creation. 7. Multi-Asset Pipeline: beyond Lucid-MS, (QNTM) is advancing FSD202 toward a Phase 2 trial for MCAS and maintains a commercial stake in Unbuzzd™. Grab the company's corporate presentation here. Pull Up (QNTM) This Morning While It's Still Early…
We have (QNTM) at the very top of our screens this morning. Take a look at (QNTM) while it's still early. After a 160% quarter and fresh potential catalysts in play, this isn't one to scroll past. If (QNTM) isn't on your screen yet, it should be. TradingView is flashing multiple bullish signals, and Barchart shows it trending above every key moving average across all timeframes. With the setup aligning technically, this chart should be on your radar right now. Also—my next update could be out at any moment—please keep a lookout for it. Sincerely, Gary Silver
Managing Editor,
Market Crux
| 
